Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination

NCT03576313 is registered in ClinicalTrials.gov with London School of Hygiene and Tropical Medicine as lead sponsor.

NCT NCT03576313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03576313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination
Lead sponsor
London School of Hygiene and Tropical Medicine
Phase
Phase 3
Overall status
Completed
Start date
August 11, 2018
Completion date
July 31, 2021
Enrollment
4,939 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria